查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1495416

a-乙醯洋地黃辛市場：依純度、依適應症分類 - 2024-2030 年全球預測

a-Acetyldigitoxin Market by Purity (Less than 95%, More than 95%), Indication (Atrial Fibrillation, Cancer Therapy, Congestive Heart Failure) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年a-乙醯洋地黃毒市場規模為2,020萬美元，2024年達2,114萬美元，預計2030年將達2,808萬美元，複合年成長率為4.81%。

α-乙醯洋地黃毒苷是一種強心配配糖體，源自紫毛洋地黃和毛毛地黃，玄參科的著名成員。其機制涉及抑制 Na+/K+-ATP 酶。這種抑制增加了細胞內的鈉濃度。結果，連鎖反應增加了心肌細胞內的細胞內鈣濃度，最終增加了心肌收縮力。 A-乙醯洋地黃毒在醫學領域用於治療某些對其他藥物無反應的心臟疾病，例如心房顫動、心房撲動，有時甚至心臟衰竭。其作用機轉與洋地黃毒苷相似，但乙醯化，可能影響吸收、分佈、代謝、排泄等藥物動力學。由於其有效作用和狹窄的治療窗，給藥需要仔細監測。全球心臟病盛行率的上升和新治療方法的引入對α-乙醯洋地黃毒市場的擴張做出了積極貢獻。與α-乙醯洋地黃辛相關的潛在副作用和毒性限制了患者和醫療保健提供者的使用。開發中國家醫療保健基礎設施的擴大以及更安全、更有效製劑的研發為α-乙醯洋地黃辛市場滲透提供了巨大的機會。

主要市場統計
基準年[2023] 2020萬美元
預計年份 [2024] 2114萬美元
預測年份 [2030] 2808萬美元
複合年成長率（%） 4.81%

區域洞察

在美洲，在醫療保健進步的推動下，a-乙醯洋地黃毒市場正在經歷適度成長，美國擁有強大的醫療保健系統、大量的研發投資和大型製藥公司。由於醫療保健的改善和慢性心臟疾病患病率的上升，拉丁美洲提供了潛在的成長機會。由於醫療保健支出不斷增加、人口老化以及心臟病患者數量迅速增加，亞太市場正在迅速擴張。中國和印度由於人口眾多、醫療保健意識高以及醫療基礎設施發達，在這一成長中處於領先地位。亞太地區因其低廉的生產成本以及面臨的挑戰（例如多元化的法規環境和專利複雜性）而吸引了全球製藥公司。 EMEA（歐洲、中東和非洲）地區呈現出多樣化的市場動態，其中歐洲由於患者意識的提高和有利的報銷政策而擁有強大的影響力。由於經濟發展、醫療保健投資不斷增加以及心血管疾病負擔日益加重，中東和非洲地區提供了新的市場機會。

FPNV定位矩陣

FPNV 定位矩陣對於評估 A-乙醯洋地黃毒市場供應商的市場定位至關重要。此矩陣提供了對供應商的全面評估，並檢驗了與商務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果，供應商被分為代表其成功程度的四個像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對 α-乙醯洋地黃毒市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻，您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他關鍵指標。此外，該分析還提供了對該行業競爭力的寶貴見解，包括研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊，供應商可以做出更明智的決策並製定有效的策略，以在市場競爭中保持領先地位。

策略分析與建議

策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對 A-乙醯洋地黃毒苷市場當前地位的全面評估使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析，以確定核心優勢和需要改進的領域。

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 越來越多的老年人口易患心臟病，全球心臟病發生率不斷上升
      • 醫療保健基礎設施和製藥創新的政府政策和資金
      • 提高對心臟病的認知和診斷
    • 抑制因素
      • 與α-乙醯洋地黃毒相關的潛在不良反應和毒性
    • 機會
      • 藥物輸送系統的技術進步提高了 a-乙醯洋地黃毒苷治療的療效和患者依從性
      • a-乙醯洋地黃毒苷在向精準醫療和個人化醫療保健規劃過渡中的潛力
    • 任務
      • 藥物意識和影響範圍有限
  • 市場區隔分析
    • 純度：擴大採用純度為 95% 或更高的 α-乙醯洋地黃毒苷來治療心房顫動和鬱血性心臟衰竭嚴重
    • 適應症：由於心血管疾病盛行率上升，對 a-乙醯洋地黃辛的需求增加
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章 a-乙醯洋地黃毒苷市場純度

  • 低於95%
  • 95%以上

第7章 A-乙醯洋地黃毒素市場（按適應症）

  • 心房顫動
  • 癌症治療
  • 心臟衰竭性鬱血性

第8章美洲A-乙醯洋地黃毒市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太A-乙醯洋地黃毒市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲/中東/非洲a-乙醯洋地黃毒市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 遠藤推出右蘭索拉唑膠囊，這是 Dexilant 的非專利藥
    • C2 PHARMA 地高辛在中國獲得核准
    • 剪切機-Smith 推出鹽酸氟奮乃靜錠劑
  • 戰略分析和建議

第12章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-950610B5BB62

[186 Pages Report] The a-Acetyldigitoxin Market size was estimated at USD 20.20 million in 2023 and expected to reach USD 21.14 million in 2024, at a CAGR 4.81% to reach USD 28.08 million by 2030.

a-Acetyldigitoxin operates as a cardiac glycoside, sourced from Digitalis purpurea and Digitalis lanata, notable members of the Scrophulariaceae family. The mechanism involves the inhibition of the Na+/K+-ATPase enzyme. Such inhibition leads to a rise in intracellular sodium levels. Consequently, a cascade reaction heightens intracellular calcium concentrations within cardiac myocytes, ultimately boosting cardiac contractility. a-Acetyldigitoxin is utilized in the medical field to treat certain heart conditions, such as atrial fibrillation, atrial flutter, and sometimes heart failure, that are not responsive to other medications. Its mechanism of action is similar to that of digitoxin, but it is acetylated, which may affect its pharmacokinetics, including absorption, distribution, metabolism, and excretion. Due to its potent effects and narrow therapeutic window, dosing a-Acetyldigitoxin requires careful monitoring. The rising global incidence of cardiac conditions, and the introduction of novel therapeutic approaches contribute positively to the expansion of a-Acetyldigitoxin market. Potential adverse effects and toxicity associated with a-Acetyldigitoxin restrain its usage among patients and healthcare providers. Expanding healthcare infrastructures in developing countries and ongoing research into safer, more effective formulations present significant opportunities for a-Acetyldigitoxin market penetration.

KEY MARKET STATISTICS
Base Year [2023] USD 20.20 million
Estimated Year [2024] USD 21.14 million
Forecast Year [2030] USD 28.08 million
CAGR (%) 4.81%

Regional Insights

In the Americas, the a-Acetyldigitoxin market is experiencing moderate growth, propelled by healthcare advancements, with the United States having a strong healthcare system, substantial R&D investments, and leading pharmaceutical entities. Latin America presents potential growth opportunities through improved healthcare accessibility and a rising prevalence of chronic heart diseases. The Asia Pacific a-Acetyldigitoxin market is rapidly expanding, driven by increased healthcare spending, an aging demographic, and a surge in heart disease cases. China and India are leading this growth due to their vast populations, enhanced healthcare awareness, and better healthcare infrastructures. The Asia Pacific region attracts global pharmaceutical firms due to lower production costs, despite facing challenges such as diverse regulatory environments and patent complexities. The EMEA region exhibits varied market dynamics, with Europe maintaining a significant market presence through advanced heightened patient awareness and favorable reimbursement policies. The Middle East and Africa offer emerging market opportunities backed by economic advancements, growing healthcare investments, and an escalating cardiovascular disease burden.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the a-Acetyldigitoxin Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Growing geriatric population vulnerable to heart diseases and the increasing global incidence of cardiac conditions
      • Governmental policies and funding in healthcare infrastructure and pharmaceutical innovation
      • Rising awareness and diagnostic rates of heart diseases
    • Market Restraints
      • Potential adverse effects and toxicity associated with a-Acetyldigitoxin
    • Market Opportunities
      • Technological advancements in drug delivery systems, improving the efficacy and patient compliance of a-Acetyldigitoxin treatments
      • Shift towards precision medicine and the potential for a-Acetyldigitoxin in personalized healthcare regimens
    • Market Challenges
      • Limited awareness and limited reachability of the drug
  • Market Segmentation Analysis
    • Purity: Increasing adoption of a-Acetyldigitoxin with over 95% purity treating critical conditions such as atrial fibrillation and congestive heart failure
    • Indication: Rising prevalence of cardiovascular diseases increasing demand for a-Acetyldigitoxin
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the a-Acetyldigitoxin Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the a-Acetyldigitoxin Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Endo Launches Dexlansoprazole Capsules, Generic Version of Dexilant

Endo International plc announced that its subordinate entity, Par Pharmaceutical, Inc., has initiated the distribution of the generic variant of Takeda's Dexilant, dexlansoprazole 30 mg capsules. This launch expands the existing product line to include both 30 mg and 60 mg delayed-release capsules, catering to a broader range of patient needs. [Published On: 2023-06-15]

C2 PHARMA Granted Approval for Digoxin in China

C2 PHARMA, a provider of ophthalmic and specialized active pharmaceutical ingredients (APIs), has the acceptance of a C-Drug Master Filing (DMF) for Digoxin by its production ally in Poland, Nobilus Ent. This critical milestone, reached after an arduous three-year endeavor disrupted by the Covid pandemic, authorizes the commercialization of both Digoxin and its micronized variant in China. These approvals extend to an array of drug product formulations, including oral and injectable versions. Extracted from the Digitalis lanata plant leaves, Digoxin stands as a pivotal cardiac glycoside in treating mild to moderate heart failure, marking a noteworthy advancement in global heart health management. This approval also enables the company to commercialize Digoxin in China. [Published On: 2023-06-14]

Upsher-Smith Launches Fluphenazine Hydrochloride Tablets

Upsher-Smith Laboratories, LLC announces the deployment of its Fluphenazine Hydrochloride Tablets, available in dosages of 1 mg, 2.5 mg, 5 mg, and 10 mg. Serving as a generic counterpart to the branded Prolixin, these tablets expand Upsher-Smith's portfolio, reinforcing its commitment to providing accessible mental health treatment options. [Published On: 2023-04-03]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the a-Acetyldigitoxin Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the a-Acetyldigitoxin Market, highlighting leading vendors and their innovative profiles. These include Biosynth Ltd, C-Squared Pharma S.a R.L., Cayman Chemical Company, Endo International plc, Medicapharma BV, Merck KGaA, Nordic Biosite, Pharmaoffer, Santa Cruz Biotechnology, Inc., Thermo Fisher Scientific Inc., and Tocris Bioscience.

Market Segmentation & Coverage

This research report categorizes the a-Acetyldigitoxin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Purity
    • Less than 95%
    • More than 95%
  • Indication
    • Atrial Fibrillation
    • Cancer Therapy
    • Congestive Heart Failure
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing geriatric population vulnerable to heart diseases and the increasing global incidence of cardiac conditions
      • 5.1.1.2. Governmental policies and funding in healthcare infrastructure and pharmaceutical innovation
      • 5.1.1.3. Rising awareness and diagnostic rates of heart diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Potential adverse effects and toxicity associated with a-Acetyldigitoxin
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in drug delivery systems, improving the efficacy and patient compliance of a-Acetyldigitoxin treatments
      • 5.1.3.2. Shift towards precision medicine and the potential for a-Acetyldigitoxin in personalized healthcare regimens
    • 5.1.4. Challenges
      • 5.1.4.1. Limited awareness and limited reachability of the drug
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Purity: Increasing adoption of a-Acetyldigitoxin with over 95% purity treating critical conditions such as atrial fibrillation and congestive heart failure
    • 5.2.2. Indication: Rising prevalence of cardiovascular diseases increasing demand for a-Acetyldigitoxin
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. a-Acetyldigitoxin Market, by Purity

  • 6.1. Introduction
  • 6.2. Less than 95%
  • 6.3. More than 95%

7. a-Acetyldigitoxin Market, by Indication

  • 7.1. Introduction
  • 7.2. Atrial Fibrillation
  • 7.3. Cancer Therapy
  • 7.4. Congestive Heart Failure

8. Americas a-Acetyldigitoxin Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific a-Acetyldigitoxin Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa a-Acetyldigitoxin Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Endo Launches Dexlansoprazole Capsules, Generic Version of Dexilant
    • 11.3.2. C2 PHARMA Granted Approval for Digoxin in China
    • 11.3.3. Upsher-Smith Launches Fluphenazine Hydrochloride Tablets
  • 11.4. Strategy Analysis & Recommendation

12. Competitive Portfolio

  • 12.1. Key Company Profiles
  • 12.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. A-ACETYLDIGITOXIN MARKET RESEARCH PROCESS
  • FIGURE 2. A-ACETYLDIGITOXIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. A-ACETYLDIGITOXIN MARKET DYNAMICS
  • FIGURE 7. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES A-ACETYLDIGITOXIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES A-ACETYLDIGITOXIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. A-ACETYLDIGITOXIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 20. A-ACETYLDIGITOXIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. A-ACETYLDIGITOXIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY LESS THAN 95%, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY LESS THAN 95%, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY MORE THAN 95%, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY MORE THAN 95%, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY CANCER THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY CANCER THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. AMERICAS A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 22. AMERICAS A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 23. AMERICAS A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 24. AMERICAS A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 25. AMERICAS A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 26. AMERICAS A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 27. ARGENTINA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 28. ARGENTINA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 29. ARGENTINA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 30. ARGENTINA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 31. BRAZIL A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 32. BRAZIL A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 33. BRAZIL A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 34. BRAZIL A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 35. CANADA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 36. CANADA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 37. CANADA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 38. CANADA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 39. MEXICO A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 40. MEXICO A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 41. MEXICO A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 42. MEXICO A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 43. UNITED STATES A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 44. UNITED STATES A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 45. UNITED STATES A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 46. UNITED STATES A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 47. UNITED STATES A-ACETYLDIGITOXIN MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 48. UNITED STATES A-ACETYLDIGITOXIN MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 56. AUSTRALIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 58. AUSTRALIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 59. CHINA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 60. CHINA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 61. CHINA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 62. CHINA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 63. INDIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 64. INDIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 65. INDIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 66. INDIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 67. INDONESIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 68. INDONESIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 69. INDONESIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 70. INDONESIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 71. JAPAN A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 72. JAPAN A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 73. JAPAN A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 74. JAPAN A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 75. MALAYSIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 76. MALAYSIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 77. MALAYSIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 78. MALAYSIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 80. PHILIPPINES A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 82. PHILIPPINES A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 83. SINGAPORE A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 84. SINGAPORE A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 85. SINGAPORE A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 86. SINGAPORE A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 88. SOUTH KOREA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 90. SOUTH KOREA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 91. TAIWAN A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 92. TAIWAN A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 93. TAIWAN A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 94. TAIWAN A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 95. THAILAND A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 96. THAILAND A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 97. THAILAND A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 98. THAILAND A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 99. VIETNAM A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 100. VIETNAM A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 101. VIETNAM A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 102. VIETNAM A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 109. DENMARK A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 110. DENMARK A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 111. DENMARK A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 112. DENMARK A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 113. EGYPT A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 114. EGYPT A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 115. EGYPT A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 116. EGYPT A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 117. FINLAND A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 118. FINLAND A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 119. FINLAND A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 120. FINLAND A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 121. FRANCE A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 122. FRANCE A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 123. FRANCE A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 124. FRANCE A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 125. GERMANY A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 126. GERMANY A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 127. GERMANY A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 128. GERMANY A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 129. ISRAEL A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 130. ISRAEL A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 131. ISRAEL A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 132. ISRAEL A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 133. ITALY A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 134. ITALY A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 135. ITALY A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 136. ITALY A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 138. NETHERLANDS A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 140. NETHERLANDS A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 141. NIGERIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 142. NIGERIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 143. NIGERIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 144. NIGERIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 145. NORWAY A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 146. NORWAY A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 147. NORWAY A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 148. NORWAY A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 149. POLAND A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 150. POLAND A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 151. POLAND A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 152. POLAND A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 153. QATAR A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 154. QATAR A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 155. QATAR A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 156. QATAR A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 157. RUSSIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 158. RUSSIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 159. RUSSIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 160. RUSSIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 162. SAUDI ARABIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 164. SAUDI ARABIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 166. SOUTH AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 169. SPAIN A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 170. SPAIN A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 171. SPAIN A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 172. SPAIN A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 173. SWEDEN A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 174. SWEDEN A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 175. SWEDEN A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 176. SWEDEN A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 178. SWITZERLAND A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 180. SWITZERLAND A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 181. TURKEY A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 182. TURKEY A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 183. TURKEY A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 184. TURKEY A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 190. UNITED KINGDOM A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 192. UNITED KINGDOM A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 193. A-ACETYLDIGITOXIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. A-ACETYLDIGITOXIN MARKET, FPNV POSITIONING MATRIX, 2023